| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| 1 | 08-07-2024 | 06-30-2024 | 10-Q | |
| 2 | 05-14-2024 | 03-31-2024 | 10-Q | |
| 3 | 02-29-2024 | 12-31-2023 | 10-K |
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
EF Hutton analyst Jason Kolbert maintains FibroBiologics (NASDAQ:FBLG) with a Buy and maintains $16 price target.
EF Hutton analyst Jason Kolbert initiates coverage on FibroBiologics (NASDAQ:FBLG) with a Buy rating and announces Price Tar...
FibroBiologics, Inc. - Common Stock (NASDAQ:FBLG) reported quarterly earnings of $0.03 per share which beat the analyst consens...
- SEC Filing
Company Holds 150+ Patents For Fibroblast-Based Therapeutics And Cures For Chronic Diseases
